The dementias associated with aging, including Alzheimer's disease, afflict a substantial segment of our aging society (5-15%), and place an extraordinary burden on the health care system. The cost of caring for patients with AD is estimated to be at least 25 billion. Despite the magnitude of this disorder, an understanding of the unique vulnerability of specific brain regions to the disease process is lacking. This pilot proposal seeks to contribute new data on the potential role of adrenal steroids in the observed vulnerability of neuronal populations in the hippocampus. The specific HYPOTHESIS we seek to test is: In AD there is an accelerated loss of glucocorticoid receptor containing neurons, and this neuronal loss will occur in hippocampal subfields which demonstrate the greatest vulnerability to the disease process. In order to arrive at examining this hypothesis, we will examine three specific aims. First, we will determine the distribution of glucocorticoid and mineralocorticoid receptor expression in human hippocampus. Second, we will determine whether aging alters the normal distribution or level of expression of these receptor subtypes. Third, we will determine if AD results in a specific loss of hippocampal neurons which contain the glucocorticoid receptor. These feasibility studies will provide, for the first time, information on corticosteroid receptors in the human brain and the effects of aging and AD on these receptors. Such data may provide new insights into mechanisms of neuronal vulnerability in AD.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Unknown (R35)
Project #
5R35AG009016-07
Application #
6098264
Study Section
Project Start
1996-06-01
Project End
1999-04-30
Budget Start
Budget End
Support Year
7
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Callahan, Linda M; Vaules, William A; Coleman, Paul D (2002) Progressive reduction of synaptophysin message in single neurons in Alzheimer disease. J Neuropathol Exp Neurol 61:384-95
Richfield, Eric K; Vonsattel, Jean-Paul; MacDonald, Marcy E et al. (2002) Selective loss of striatal preprotachykinin neurons in a phenocopy of Huntington's disease. Mov Disord 17:327-32
Chang, J W; Young, D A; Coleman, P D et al. (2001) Two-dimensional gel analysis of secreted proteins induced by interleukin-1 beta in rat astrocytes. Neurochem Int 39:349-59
Yao, P J; Weimer, J M; O'Herron, T M et al. (2000) Clathrin assembly protein AP-2 is detected in both neurons and glia, and its reduction is prominent in layer II of frontal cortex in Alzheimer's disease. Neurobiol Aging 21:921-9
Yermakova, A; O'Banion, M K (2000) Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des 6:1755-76
Utal, A K; Coleman, P D (1999) Non-HPLC separation of water-soluble choline metabolites by two-dimensional high voltage electrophoresis and thin layer chromatography. J Neurosci Methods 90:13-21
Yermakova, A V; Rollins, J; Callahan, L M et al. (1999) Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 58:1135-46
Morsch, R; Simon, W; Coleman, P D (1999) Neurons may live for decades with neurofibrillary tangles. J Neuropathol Exp Neurol 58:188-97
Callahan, L M; Vaules, W A; Coleman, P D (1999) Quantitative decrease in synaptophysin message expression and increase in cathepsin D message expression in Alzheimer disease neurons containing neurofibrillary tangles. J Neuropathol Exp Neurol 58:275-87
Yao, P J; Morsch, R; Callahan, L M et al. (1999) Changes in synaptic expression of clathrin assembly protein AP180 in Alzheimer's disease analysed by immunohistochemistry. Neuroscience 94:389-94

Showing the most recent 10 out of 39 publications